Sign up

Palo Alto Investors LP

$723.7M assets · 52 holdings · Q2 2026 · Filed 19 AUG 2026

About Palo Alto Investors LP’s 13F portfolio

Palo Alto Investors LP is an institutional investment manager that discloses its US-listed holdings each quarter through an SEC Form 13F filing. As of , Palo Alto Investors LP reported $723.7M across 52 US-listed positions (). Its largest position is PTC THERAPEUTICS INC (PTCT) at 10% of the reported book, and its ten biggest holdings make up 61% of the portfolio. Browse every manager in the fund managers directory, or see the legendary investors we track on the superinvestors page.

$723.7M
Assets (13F)
#2,924
of 8,845 by size
52
Holdings
61%
Top-10 weight
8
Buys
17
Sells
Top holdings · Q2 2026
52 total
#StockPrice% of portfolioSharesValue
1
NASDAQ: PTCT
PTC THERAPEUTICS INC
$56.42
−3.27%
10%
919K$75.0M
2
NASDAQ: ACAD
ACADIA PHARMACEUTICALS INC
$17.11
−2.73%
10%
2.9M$72.5M
3
NASDAQ: INSM
INSMED INC
$141.33
−2.17%
6.1%
414K$44.1M
4
NASDAQ: MIRM
MIRUM PHARMACEUTICALS INC
$96.13
+0.65%
5.6%
349K$40.8M
5
NASDAQ: ANAB
ANAPTYSBIO INC
$46.63
−1.62%
5.6%
603K$40.7M
6
NASDAQ: BMRN
BIOMARIN PHARMACEUTICAL INC
$60.41
−1.64%
5.4%
683K$39.1M
7
NASDAQ: DYN
DYNE THERAPEUTICS INC
$15.50
−3.31%
5.1%
1.6M$36.6M
8
NASDAQ: UTHR
UNITED THERAPEUTICS CORP
$554.73
−0.78%
4.7%
63K$33.9M
9
NASDAQ: IRON
DISC MEDICINE INC
$75.14
−1.27%
4.2%
417K$30.5M
10
NASDAQ: BIIB
BIOGEN INC
$249.59
+1.00%
4.2%
140K$30.3M
11
NASDAQ: IOVA
IOVANCE BIOTHERAPEUTICS INC
$6.90
−5.61%
3.0%
5.3M$22.0M
12
NASDAQ: RARE
ULTRAGENYX PHARMACEUTICAL IN
$16.48
−4.30%
2.8%
596K$19.9M
13
NASDAQ: NVCR
NOVOCURE LTD
$10.71
+0.19%
2.7%
1.3M$19.4M
14
NASDAQ: SNDX
SYNDAX PHARMACEUTICALS INC
$8.72
−4.49%
2.6%
865K$18.9M
15
NASDAQ: ANNX
ANNEXON INC
$3.10
−9.09%
2.3%
2.9M$16.8M
16
NASDAQ: BCAX
BICARA THERAPEUTICS INC
$8.44
−7.46%
2.3%
550K$16.3M
17
NASDAQ: CDNA
CAREDX INC
$70.00
−2.67%
2.1%
532K$15.2M
18
NASDAQ: CLDX
CELLDEX THERAPEUTICS INC
$27.42
−1.93%
2.1%
400K$14.9M
19
NASDAQ: CMPX
COMPASS THERAPEUTICS INC
$0.69
+1.43%
1.8%
5.8M$12.8M
20
NASDAQ: ALKS
ALKERMES PLC
$44.94
−2.69%
1.8%
243K$12.7M
21
NASDAQ: TRAX
FIRST TRACKS BIOTHERAPEUTICS
—
—
1.7%
603K$12.1M
22
NASDAQ: PRTA
PROTHENA CORP PLC
$8.22
−2.14%
1.5%
1.1M$11.2M
23
NASDAQ: TVTX
TRAVERE THERAPEUTICS INC
$47.00
−2.69%
1.3%
168K$9.5M
24
NASDAQ: TSHA
TAYSHA GENE THERAPIES INC
$3.72
−1.33%
1.3%
1.4M$9.5M
25
NASDAQ: ACRS
ACLARIS THERAPEUTICS INC
$3.44
−1.71%
1.2%
1.6M$8.5M

Showing 1–25 of 52 positions on this page reported in this 13F.

Sector allocation
  • Healthcare98%
  • Financial Services0.3%
Recent activity · vs 2026-03-31
Bought8
  • AddedMIRMMIRUM PHARMACEUTICALS INC+7.3%$40.8M
  • AddedIRONDISC MEDICINE INC+3.7%$30.5M
  • AddedCLDXCELLDEX THERAPEUTICS INC+34.9%$14.9M
  • AddedCMPXCOMPASS THERAPEUTICS INC+285%$12.8M
  • NewTRAXFIRST TRACKS BIOTHERAPEUTICS—$12.1M
  • NewSGMTSAGIMET BIOSCIENCES INC-A—$1.9M
  • NewNAMSNEWAMSTERDAM PHARMA CO NV—$1.5M
  • AddedVSTMVERASTEM INC+25.8%$1.2M
Sold17
  • ReducedPTCTPTC THERAPEUTICS INC−0.3%$75.0M
  • ReducedACADACADIA PHARMACEUTICALS INC−0.3%$72.5M
  • ReducedINSMINSMED INC−0.3%$44.1M
  • ReducedANABANAPTYSBIO INC−5.4%$40.7M
  • ReducedBMRNBIOMARIN PHARMACEUTICAL INC−0.4%$39.1M
  • ReducedDYNDYNE THERAPEUTICS INC−0.3%$36.6M
  • ReducedUTHRUNITED THERAPEUTICS CORP−0.4%$33.9M
  • ReducedBIIBBIOGEN INC−0.3%$30.3M
  • ReducedIOVAIOVANCE BIOTHERAPEUTICS INC−16.6%$22.0M
  • ReducedPRTAPROTHENA CORP PLC−5.4%$11.2M

Reading Palo Alto Investors LP’s 13F portfolio

Palo Alto Investors LP’s $723.7M 13F book is spread across 52 reported positions and is highly concentrated — its ten largest positions alone are 61% of the portfolio. A book this concentrated means a small group of names drives most of its performance. Its five largest positions are PTCT, ACAD, INSM, MIRM and ANAB, led by PTC THERAPEUTICS INC (PTCT) at 10% of the portfolio. The heaviest sector exposure is Healthcare (98%), then Financial Services (0%).

What Palo Alto Investors LP changed last quarter

Between 2026-03-31 and Q2 2026, Palo Alto Investors LP was a net seller: it opened 3 new positions and added to 5 more, while trimming 15 and closing 2 outright. Against a 52-name book, that is moderate turnover, pointing to steady rotation within the portfolio. Its largest new or increased position was MIRUM PHARMACEUTICALS INC (MIRM), and its biggest reduction was PTC THERAPEUTICS INC (PTCT).

What a 13F does and doesn’t reveal

A 13F captures only Palo Alto Investors LP’s long positions in US-listed stocks at a single quarter-end, so it is best read as a lagged snapshot rather than a live portfolio. It won’t show shorts, cash, bonds, or holdings listed outside the US, and it never reveals the price paid or the reasoning behind a trade. The signal is in the pattern over time: which names Palo Alto Investors LP is building up, trimming, or exiting, and how concentrated the book stays from quarter to quarter.

Frequently asked questions

What is an SEC 13F filing?

A Form 13F is a report that every institutional investment manager with at least $100 million in US-listed securities must file with the SEC within 45 days of each quarter's end. It lists the manager's long positions in US-listed stocks and certain options, with the share count and market value of each. Palo Alto Investors LP's profile on this page is built directly from those filings.

How current is the 13F data on Palo Alto Investors LP's page?

It reflects Palo Alto Investors LP's most recently filed 13F, currently the quarter ending Q2 2026. Because managers have up to 45 days after a quarter closes to file, a 13F is always a slightly lagged view rather than a live portfolio. When Palo Alto Investors LP files its next quarterly report, this page refreshes automatically.

Can I see Palo Alto Investors LP's complete list of holdings?

This page highlights Palo Alto Investors LP's largest positions rather than all 52 names in the filing. The complete, position-by-position 13F is public and available from the SEC's EDGAR database under Palo Alto Investors LP's filings.

Does a 13F show everything Palo Alto Investors LP owns?

No. A 13F only covers long positions in US-listed stocks and certain options. It leaves out short positions, cash, bonds, commodities, foreign-listed stocks, and private holdings, so it is a partial view of Palo Alto Investors LP's book rather than its full strategy or total assets.

Is 13F data investment advice?

No. Everything here is educational. 13F positions are disclosed with a delay, cover only long US-listed holdings, and never explain why Palo Alto Investors LP made a trade or at what price. Treat it as a research lens, not a recommendation, and speak with a licensed financial advisor before making investment decisions.

Not investment advice. Holdings data comes from public SEC Form 13F filings, which are filed with a delay of up to 45 days and may be amended later. It describes historical, disclosed positions in US-listed securities only, meaning no shorts, cash, or foreign holdings, and it is not a recommendation. Always do your own research and speak with a licensed financial advisor before making investment decisions.